Eric Jia-Sobota

It seems that there may be a new Valley of Death on the horizon of COVID therapeutic development. Earlier this month (9 JUL) NIAID posted a Funding Opportunities Announcement soliciting proposals related to COVID therapeutic development through their Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern program (RFA-AI-21-050: Antiviral Drug Discovery (AViDD) Centers […]

Earlier this month the Army Contracting Command published an amendment to solicitation W911QY-20-S-C001 related to Area of Interest 5, oral antiviral therapeutics. This is a procurement solicitation and specifically the USG is looking for direct-acting antivirals for COVID-19 high-risk patients. Successful offerors will be able to deliver 500,000 treatment courses of the anti-viral within eight

For the past 18 months companies have been confused and frustrated by the shifting USG policies regarding the development of therapeutics as part of the COVID-19 response. BARDA was back and forth as parts of the BAA were suspended, unsuspended, and resuspended. The American rescue Plan legislation was passed about six months ago and although

The Joint Army Contracting Command and the Joint COVID Response Division (ACC-JCRD) recently published a solicitation seeking Commercial Solutions to decrease US reliance on fragile global supply chains and increase preparedness for future pandemics. The solicitation seeks to establish, expand, and accelerate the availability of domestically-produced supplies in several different areas, some of which may

Recently, the Coalition for Epidemic Preparedness Innovations (CEPI) published a call for proposals that is open from 28 JAN 2021 to 28 MAY 2021 and can be found here [CEPICfPCallText.pdf]. Trials that expand access in low and middle income countries is strongly encouraged. The objective is to expand access to vaccines that are already in

Recently BARDA published information about the COVID programs the USG is supporting through collaboration between HHS and DoD. Some of that information is summarized in the  table below. In the rush to respond to the COVID pandemic the portfolio became unbalanced, especially regarding therapeutics. With the new administration there is interest and funding available to

During his first week in office President Biden followed through on his promise for swift executive action to address COVID. One Executive Order (EO) focused on COVID care and treatments (Improving and Expanding Access to Care and Treatments for COVID-19). One section of this EO aims to accelerate the development of novel therapies. It call

Putting the best foot forward in the white paper is very important and EverGlade can help you take that step successfully. Our staff has over 40 years of cumulative experience on both sides of the table- preparation of white papers and their review. We have the same experience with the preparation of full proposals and